Scholar Rock (SRRK) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $40.64, +2.63% vs the prior close of $39.60.
- Volume 1.94M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SRRK rises 2.6% to $40.64. Closed at $40.64, +2.63% vs the prior close of $39.60. Day range $39.32–$41.35, opened at $39.99.
SRRK daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — SRRK rises 2.6% to $40.64
- Closed at $40.64, +2.63% vs the prior close of $39.60. Day range $39.32–$41.35, opened at $39.99.
- Volume was 1.94M shares, 1.2x its 50-day average of 1.68M.
- Price is -20.2% vs its 50-day average ($50.95) and -15.8% vs its 200-day average ($48.27).
- 52-week range $27.07–$61.76; today's close sits at 39% of that range, 34.2% below the 52-week high.
Oct 14, 2026 — SRRK dips 2.3% to $39.60, a 6-month low, 8 down days in a row
- Closed at $39.60, -2.27% vs the prior close of $40.52. Day range $39.20–$40.91, opened at $40.27.
- Volume was 1.28M shares, 0.8x its 50-day average of 1.67M.
- Price is -22.5% vs its 50-day average ($51.09) and -18.0% vs its 200-day average ($48.29).
- 52-week range $27.07–$61.76; today's close sits at 36% of that range, 35.9% below the 52-week high.
- That makes 8 straight losses.
Oct 13, 2026 — SRRK slides 3.4% to $40.52, a 6-month low, 7 down days in a row
- Closed at $40.52, -3.39% vs the prior close of $41.94. Day range $40.52–$41.83, opened at $41.71.
- Volume was 1.10M shares, 0.7x its 50-day average of 1.67M.
- Price is -20.9% vs its 50-day average ($51.25) and -16.1% vs its 200-day average ($48.32).
- 52-week range $27.07–$61.76; today's close sits at 39% of that range, 34.4% below the 52-week high.
- That makes 7 straight losses.
Oct 12, 2026 — SRRK dips 0.6% to $41.94, a 6-month low, 6 down days in a row
- Closed at $41.94, -0.59% vs the prior close of $42.19. Day range $41.38–$42.52, opened at $41.94.
- Volume was 1.63M shares, 1.0x its 50-day average of 1.65M.
- Price is -18.3% vs its 50-day average ($51.36) and -13.2% vs its 200-day average ($48.35).
- 52-week range $27.07–$61.76; today's close sits at 43% of that range, 32.1% below the 52-week high.
- That makes 6 straight losses.
Oct 9, 2026 — SRRK ends flat (-0.0%) to $42.19, a 6-month low, 5 down days in a row
- Closed at $42.19, -0.02% vs the prior close of $42.20. Day range $41.81–$42.81, opened at $42.18.
- Volume was 1.26M shares, 0.8x its 50-day average of 1.67M.
- Price is -18.0% vs its 50-day average ($51.47) and -12.8% vs its 200-day average ($48.37).
- 52-week range $27.07–$61.76; today's close sits at 44% of that range, 31.7% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 — SRRK ends flat (+0.0%) to $42.20 on 2.0x normal volume
- Closed at $42.20, +0.00% vs the prior close of $42.20. Day range $41.12–$43.12, opened at $41.87.
- Volume was 3.30M shares, 2.0x its 50-day average of 1.62M — unusually heavy trading.
- Price is -18.2% vs its 50-day average ($51.60) and -12.8% vs its 200-day average ($48.38).
- 52-week range $27.07–$61.76; today's close sits at 44% of that range, 31.7% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — SRRK dips 0.6% to $42.20, a 6-month low, 3 down days in a row
- Closed at $42.20, -0.59% vs the prior close of $42.45. Day range $41.95–$44.20, opened at $42.28.
- Volume was 1.56M shares, 1.0x its 50-day average of 1.61M.
- Price is -18.4% vs its 50-day average ($51.74) and -12.8% vs its 200-day average ($48.39).
- 52-week range $27.07–$61.76; today's close sits at 44% of that range, 31.7% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — SRRK dips 2.2% to $42.45, a 6-month low
- Closed at $42.45, -2.19% vs the prior close of $43.40. Day range $41.89–$43.75, opened at $43.58.
- Volume was 1.86M shares, 1.2x its 50-day average of 1.60M.
- Price is -18.2% vs its 50-day average ($51.89) and -12.3% vs its 200-day average ($48.39).
- 52-week range $27.07–$61.76; today's close sits at 44% of that range, 31.3% below the 52-week high.
Oct 5, 2026 — SRRK slides 7.3% to $43.40, a 6-month low on 2.2x normal volume
- Closed at $43.40, -7.28% vs the prior close of $46.81. Day range $42.47–$47.19, opened at $47.08.
- Volume was 3.35M shares, 2.2x its 50-day average of 1.55M — unusually heavy trading.
- Price is -16.6% vs its 50-day average ($52.01) and -10.3% vs its 200-day average ($48.40).
- 52-week range $27.07–$61.76; today's close sits at 47% of that range, 29.7% below the 52-week high.
Oct 2, 2026 — SRRK rises 1.4% to $46.81
- Closed at $46.81, +1.41% vs the prior close of $46.16. Day range $46.08–$47.80, opened at $46.74.
- Volume was 1.24M shares, 0.8x its 50-day average of 1.54M.
- Price is -10.2% vs its 50-day average ($52.10) and -3.3% vs its 200-day average ($48.40).
- 52-week range $27.07–$61.76; today's close sits at 57% of that range, 24.2% below the 52-week high.
SRRK latest news & SEC filings
Every SEC filing by or about SRRK in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 25, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 23, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 14, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$109.90M (prior year -$110.03M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.84 (prior year -$0.98) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Flier Jeffrey S. sold 1,568 shares at $53.53 (≈$83.94K) on Jul 1, 2026
- Flier Jeffrey S. sold 15 shares at $54.88 (≈$823) on Jul 1, 2026
- Flier Jeffrey S. sold 1,470 shares at $54.24 (≈$79.73K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gilman Michael sold 43 shares at $54.81 (≈$2.36K) on Jul 1, 2026
- Gilman Michael sold 1,346 shares at $53.54 (≈$72.06K) on Jul 1, 2026
- Gilman Michael sold 1,155 shares at $54.23 (≈$62.64K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Burow Kristina sold 2,105 shares at $53.49 (≈$112.60K) on Jul 1, 2026
- Burow Kristina sold 948 shares at $54.28 (≈$51.46K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade SRRK
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 3, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.47% (largest 7.3%).
- Liquidity: about 1.99M shares (≈$80.90M) trade per day on average.
- 52-week position: $40.64 vs a range of $27.07–$61.76 (39% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Joshua Reed sold 948 shares on Jul 1, 2026.
- Latest filings: 8-K Sep 15, 2026; 8-K Sep 14, 2026; 8-K Aug 6, 2026.
- Share count: 121.79M shares outstanding (Aug 3, 2026), +26.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SRRK market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 39.99 | 41.35 | 39.32 | 40.64 | 1.94M |
| Oct 14, 2026 | 40.27 | 40.91 | 39.20 | 39.60 | 1.28M |
| Oct 13, 2026 | 41.71 | 41.83 | 40.52 | 40.52 | 1.10M |
| Oct 12, 2026 | 41.94 | 42.52 | 41.38 | 41.94 | 1.63M |
| Oct 9, 2026 | 42.18 | 42.81 | 41.81 | 42.19 | 1.26M |
| Oct 8, 2026 | 41.87 | 43.12 | 41.12 | 42.20 | 3.30M |
| Oct 7, 2026 | 42.28 | 44.20 | 41.95 | 42.20 | 1.56M |
| Oct 6, 2026 | 43.58 | 43.75 | 41.89 | 42.45 | 1.86M |
| Oct 5, 2026 | 47.08 | 47.19 | 42.47 | 43.40 | 3.35M |
| Oct 2, 2026 | 46.74 | 47.80 | 46.08 | 46.81 | 1.24M |
| Oct 1, 2026 | 48.32 | 48.82 | 46.07 | 46.16 | 1.06M |
| Sep 30, 2026 | 48.42 | 49.60 | 48.11 | 48.32 | 1.29M |
| Sep 29, 2026 | 48.98 | 49.35 | 47.47 | 47.75 | 1.07M |
| Sep 28, 2026 | 48.10 | 49.98 | 47.76 | 49.13 | 1.57M |
| Sep 25, 2026 | 49.19 | 49.46 | 48.19 | 48.63 | 1.88M |
| Sep 24, 2026 | 50.08 | 50.40 | 48.21 | 48.61 | 2.03M |
| Sep 23, 2026 | 51.19 | 51.74 | 49.25 | 49.85 | 2.49M |
| Sep 22, 2026 | 48.07 | 51.67 | 48.07 | 51.19 | 3.75M |
| Sep 21, 2026 | 47.35 | 49.15 | 46.54 | 48.16 | 2.90M |
| Sep 18, 2026 | 48.02 | 48.53 | 45.88 | 46.65 | 3.25M |
About Scholar Rock
Scholar Rock (SRRK) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1727196.
SRRK board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Srinivas Akkaraju | Director | Jun 8, 2026 |
| Richard Brudnick | Director | Jun 8, 2026 |
| Kristina Burow | Director | Jul 6, 2026 |
| Jeffrey S. Flier | Director | Jul 6, 2026 |
| Michael Gilman | Director | Jul 6, 2026 |
| David Hallal | Chief Executive Officer | Sep 23, 2026 |
| Katie Peng | Director | Jul 6, 2026 |
| Joshua Reed | Director | Jul 6, 2026 |
| Akshay Vaishnaw | President of R&D | Apr 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Hallal | Chief Executive Officer | Sep 23, 2026 |
| Junlin Ho | GENERAL COUNSEL | Feb 19, 2026 |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | Feb 19, 2026 |
| Caryn Parlavecchio | CHRO | Feb 19, 2026 |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Feb 25, 2026 |
| Vikas Sinha | Chief Financial Officer | Apr 20, 2026 |
| Akshay Vaishnaw | President of R&D | Apr 20, 2026 |
| Keith Woods | Chief Operating Officer | Sep 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Joshua Reed | Sale | 948 | $54.28 |
| Jul 1, 2026 | Joshua Reed | Sale | 2,105 | $53.50 |
| Jul 1, 2026 | Katie Peng | Sale | 2,988 | $53.56 |
| Jul 1, 2026 | Katie Peng | Sale | 21 | $54.96 |
| Jul 1, 2026 | Katie Peng | Sale | 2,437 | $54.25 |
| Jul 1, 2026 | Michael Gilman | Sale | 43 | $54.81 |
| Jul 1, 2026 | Michael Gilman | Sale | 1,346 | $53.54 |
| Jul 1, 2026 | Michael Gilman | Sale | 1,155 | $54.23 |
| Jul 1, 2026 | Kristina Burow | Sale | 2,105 | $53.49 |
| Jul 1, 2026 | Kristina Burow | Sale | 948 | $54.28 |
| Jul 1, 2026 | Jeffrey S. Flier | Sale | 1,568 | $53.53 |
| Jul 1, 2026 | Jeffrey S. Flier | Sale | 15 | $54.88 |
| Jul 1, 2026 | Jeffrey S. Flier | Sale | 1,470 | $54.24 |
| Apr 16, 2026 | Vikas Sinha | Sale | 10,410 | $49.57 |
| Apr 16, 2026 | Akshay Vaishnaw | Sale | 12,246 | $49.57 |
SRRK financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-377.94M | -3.29 | $-300.04M |
| Dec 31, 2024 | — | $-246.29M | -2.47 | $-200.95M |
| Dec 31, 2023 | — | $-165.79M | -1.99 | $-145.23M |
| Dec 31, 2022 | $33.19M | $-134.50M | -2.26 | $-132.69M |
| Dec 31, 2021 | $18.82M | $-131.80M | -3.59 | $-126.79M |
Latest balance sheet: total assets $523.54M, total liabilities $269.76M, cash $437.09M (as of Jun 30, 2026).
SRRK earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $52.64 |
| May 7, 2026 | 8-K Item 2.02 (results) | $46.45 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $44.31 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $43.56 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $37.41 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $34.62 |
| May 14, 2025 | 8-K Item 2.02 (results) | $30.54 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $35.96 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $26.66 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on SRRK
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.